Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 11Lymphoid 10Myeloid 3Sarcoma 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1478Leukemia, Myeloid, Acute 1239Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Leukemia 745Precursor Cell Lymphoblastic Leukemia-Lymphoma 704Myeloproliferative Disorders 631Leukemia, Myelomonocytic, Chronic 455Lymphoma, Non-Hodgkin 447Primary Myelofibrosis 430Multiple Myeloma 423Leukemia, Lymphocytic, Chronic, B-Cell 408Hodgkin Disease 384Lymphoma 343Leukemia, Myeloid, Chronic-Phase 335Blast Crisis 282Polycythemia Vera 267Leukemia, Myeloid, Accelerated Phase 263Lymphoma, Follicular 254Lymphoma, Mantle-Cell 253Burkitt Lymphoma 246Lymphoma, Large B-Cell, Diffuse 244Lymphoma, B-Cell, Marginal Zone 225Congenital Abnormalities 215Lymphoma, Large-Cell, Immunoblastic 201Myelodysplastic-Myeloproliferative Diseases 199Thrombocythemia, Essential 197Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 196Anemia, Refractory, with Excess of Blasts 194Hematologic Neoplasms 193Neoplasms, Plasma Cell 184

Interventions

sonidegib 1ruxolitinib 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hemorrhagic Disorders × Myeloid × Clear all
NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡